Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$12.97 USD

12.97
3,762,235

+0.24 (1.89%)

Updated Jul 2, 2024 04:00 PM ET

After-Market: $12.95 -0.02 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Novavax, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 579 1,347 1,527 805 82
Receivables 297 82 455 262 8
Notes Receivable 0 0 0 0 0
Inventories 42 37 0 0 0
Other Current Assets 226 237 174 181 8
Total Current Assets 1,144 1,703 2,155 1,248 97
Net Property & Equipment 306 294 229 180 11
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 127 126 136 141 57
Deposits & Other Assets 35 28 57 13 8
Total Assets 1,797 2,259 2,577 1,582 173
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 325 0 0 0
Accounts Payable 133 217 127 54 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 5 27 131 106 0
Accrued Expenses 395 591 674 142 20
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1,103 1,300 1,459 277 3
Total Current Liabilities 1,635 2,460 2,390 580 26
Mortgages 0 0 0 0 0
Deferred Taxes/Income 622 179 173 0 3
Convertible Debt 168 166 323 322 321
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 56 31 0 40 0
Other Non-Current Liabilities 33 56 42 13 10
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,514 2,893 2,928 955 359
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 0
Capital Surplus 4,192 3,738 3,352 2,535 1,261
Retained Earnings -4,821 -4,276 -3,618 -1,874 -1,432
Other Equity 3 -6 -1 7 -13
Treasury Stock 92 91 85 42 3
Total Shareholder's Equity -717 -634 -352 627 -186
Total Liabilities & Shareholder's Equity 1,797 2,259 2,577 1,582 173
Total Common Equity -717 -634 -352 627 -186
Shares Outstanding 118.70 78.50 75.60 63.60 32.30
Book Value Per Share -6.04 -8.08 -4.65 9.86 -5.76

Fiscal Year End for Novavax, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 491 579 662 516 635
Receivables 21 297 124 395 113
Notes Receivable 0 0 0 0 0
Inventories 16 42 70 23 34
Other Current Assets 199 226 152 193 189
Total Current Assets 727 1,144 1,007 1,128 971
Net Property & Equipment 291 306 301 300 307
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 123 127 124 128 130
Deposits & Other Assets 31 35 35 33 31
Total Assets 1,354 1,797 1,657 1,685 1,543
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 58 133 102 87 125
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 6 5 1 1 1
Accrued Expenses 257 395 311 458 519
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 483 1,103 1,054 1,050 1,274
Total Current Liabilities 804 1,635 1,469 1,596 1,919
Mortgages 0 0 0 0 0
Deferred Taxes/Income 841 622 609 607 274
Convertible Debt 168 168 168 167 167
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 55 56 53 31 31
Other Non-Current Liabilities 352 37 38 48
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,221 2,514 2,336 2,440 2,438
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 4,205 4,192 4,067 3,856 3,768
Retained Earnings -4,969 -4,821 -4,643 -4,512 -4,570
Other Equity -11 3 -12 -8 -3
Treasury Stock 94 92 92 91 91
Total Shareholder's Equity -867 -717 -678 -755 -896
Total Liabilities & Shareholder's Equity 1,354 1,797 1,657 1,685 1,543
Total Common Equity -867 -717 -678 -755 -896
Shares Outstanding 140.40 118.70 118.70 86.30 86.30
Book Value Per Share -6.18 -6.04 -5.71 -8.74 -10.38